Literature DB >> 2538227

Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.

C Jaxel1, K W Kohn, M C Wani, M E Wall, Y Pommier.   

Abstract

Twenty-two compounds related to camptothecin, a known inhibitor of eukaryotic topoisomerase I, were studied. The following effects on the actions of topoisomerase I were observed and were well correlated among most of the compounds studied: (a) inhibition of the first-order rate of relaxation of supercoiled DNA; (b) conversion of supercoiled DNA to nicked circles; and (c) single-strand cleavage of linear DNA at specific sites. The locations of the stimulated cleavage sites were the same for all of the active derivatives. Stereochemistry and the positions of substituents were found to be crucial for the presence or absence of effects on topoisomerase I, indicating that the compounds interact with an asymmetrical receptor site on the enzyme or enzyme-DNA complex. From the structure-activity relations, the regions of interaction between the camptothecin ring system and the receptor site were inferred. Striking correlations were observed between activity against topoisomerase I and reported activity against murine leukemias, indicating that an action on topoisomerase I is responsible for the antitumor activity of the camptothecins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2538227

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  72 in total

Review 1.  Camptothecin delivery methods.

Authors:  A Hatefi; B Amsden
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

2.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

Review 3.  DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.

Authors:  Yves Pommier; Elisabetta Leo; HongLiang Zhang; Christophe Marchand
Journal:  Chem Biol       Date:  2010-05-28

Review 4.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

Review 5.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

6.  Study of the Binding between Camptothecin Analogs and FTO by Spectroscopy and Molecular Docking.

Authors:  Ting Ren; Zechun Wang; Lijiao Zhang; Ning Wang; Xinxin Han; Ruiyong Wang; Junbiao Chang
Journal:  J Fluoresc       Date:  2017-04-11       Impact factor: 2.217

7.  Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitors.

Authors:  Maris A Cinelli; Andrew Morrell; Thomas S Dexheimer; Evan S Scher; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2008-07-17       Impact factor: 7.446

8.  Stable supersaturated aqueous solutions of silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin via chemical conversion in the presence of a chemically modified beta-cyclodextrin.

Authors:  Tian-Xiang Xiang; Bradley D Anderson
Journal:  Pharm Res       Date:  2002-08       Impact factor: 4.200

9.  The synergism between Belotecan and cisplatin in gastric cancer.

Authors:  Joo Young Jung; Sang Hyun Song; Tae-Young Kim; Jung Hyun Park; Hyun-Soon Jong; Seock-Ah Im; Tae-You Kim; Yung-Jue Bang; Noe Kyoung Kim
Journal:  Cancer Res Treat       Date:  2006-09-30       Impact factor: 4.679

10.  Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.

Authors:  Maris A Cinelli; Brenda Cordero; Thomas S Dexheimer; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem       Date:  2009-09-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.